Study on the efficacy and tolerability of amisulpride in medical/surgical inpatients with delirium admitted to a general hospital - 20/10/09
, E. Fuente b, E. Bailles a, S. Matrai a
Corresponding author. Psychiatry Department, Neuroscience Institute, Hospital Clínico de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain. Tel.: +34 93 2275477; fax: +34 93 2275477.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Purpose |
To evaluate the efficacy and safety of amisulpride in medical inpatients who present with delirium.
Method |
Open label prospective study with 7-day follow-up. Forty hospital inpatients with delirium were recruited, seven of whom died and two of whom refused medication. The average dose of amisulpride for delirium treatment was 200–300mg/day. Daily assessments were performed with Delirium Rating Scale (DRS), Positive Subscale of the Positive and Negative Syndrome Scale (PANSS-P), Mini Mental State Examination (MMSE), Neurological Subscale of the UKU side effect rating scale. Variance analysis was performed through repeated measurements, with the general linear model with paired comparisons and Bonferroni correction for each measured variable.
Results |
Patients showed significant improvement on the DRS from the first day of treatment DRS=17.55 until day 7 DRS=7.26 (F=92.485; p<0.001), psychotic symptoms improved from first day PANSS-P=18.26 to last day PANSS-P=9.35 (F=144.83; p<0.001). Cognitive status showed a significant improvement from day 2 MMSE=18.71 until day 7 MMSE=24.06 (F=96.56; p<0.001), and the neurological subscale of the UKU side effect rating scale showed a significant improvement the last day with respect to baseline pretreatment level (F=7.539; p=0.01).
Conclusions |
These results suggest a good response to amisulpride in the acute phase of delirium, although further randomized controlled studies must be performed.
Le texte complet de cet article est disponible en PDF.Keywords : Delirium, Antipsychotics, Efficacy, Amisulpride
Plan
Vol 24 - N° 7
P. 450-455 - octobre 2009 Retour au numéro
Article précédent
- Personality problems are considerably associated with somatic morbidity and health care utilisation
- I. Olssøn, A.A. Dahl
- Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients
- D. Clark, O.A. Skrobot, I. Adebiyi, M.T. Susce, J. de Leon, AI.F. Blakemore, M.J. Arranz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?